Not available
Quote | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Last: | $142.29 |
---|---|
Change Percent: | -0.04% |
Open: | $141.97 |
Close: | $142.29 |
High: | $142.86 |
Low: | $140.51 |
Volume: | 641,937 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...
Message Board Posts | Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Subject | By | Source | When |
---|---|---|---|
https://finance.yahoo.com/m/ac97a7cc-59a6-39e8-8438-16d26de87a27/voyager%2C-neur | TheFinalCD | investorshub | 01/09/2023 7:23:31 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Reports Third Quarter 2022 Financial Result | whytestocks | investorshangout | 11/01/2022 3:55:56 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences Presents INGREZZA (valbenazine) Data on Sus | whytestocks | investorshangout | 09/19/2022 12:45:51 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present Study Findings on Evolving Tardi | whytestocks | investorshangout | 09/15/2022 7:35:48 PM |
whytestocks: $NBIX News Article - Neurocrine Biosciences to Present New INGREZZA (valbenazine) and O | whytestocks | investorshangout | 09/10/2021 7:05:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 PR Newswire - CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitatio...
2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $175.00 for NBIX on 2024-05-13 16:13:00. The adjusted price target was set to $175.00. At the time of the announcement, NBIX was trading at $136.15. The overall price target consensus is at $1...
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 PR Newswire CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce...